|1.||Creţu, Elena: 1 article (10/2012)|
|2.||Vasincu, Al: 1 article (10/2012)|
|3.||Trifan, Adriana: 1 article (10/2012)|
|4.||Miron, Anca: 1 article (10/2012)|
02/01/1984 - "A broad phase II trial of elliptinium was conducted in 105 evaluable patients with advanced solid tumors. "
12/01/1982 - "Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)."
06/01/1982 - "Twenty-three patients with advanced solid tumors received 9-hydroxy-2N-methyl-ellipticinium acetate at a single daily i.v. dose of 15-80 mg/m2 for 5 consecutive days, repeated every 3 weeks. "
06/15/1987 - "Celiptium, a cationic and amphiphilic drug currently employed in cancer chemotherapy, was found to be accumulated against its concentration gradient by the bacterium Streptococcus pneumoniae. "
02/01/1984 - "Daily subcutaneous injections of 5 micrograms hydroxy-N-methyl elliptinium for 4 weeks in a high mammary tumor strain of SHN virgin mice was found to decrease the number of precancerous mammary hyperplastic alveolar nodules (HAN) associated with the increase in the number of ghosts, the remnants of regressed HAN. "
08/01/1993 - "Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice."
01/01/1996 - "The antitumor activity of S 16020-2, a new olivacine derivative, was investigated in vivo and compared with that of Adriamycin and elliptinium acetate in a panel of murine (P388 leukemia, M5076 sarcoma, Lewis lung carcinoma, and B16 melanoma) and human (NCI-H460 non-small-cell lung and MCF7 breast carcinomas) tumor models. "
|3.||Breast Neoplasms (Breast Cancer)
01/01/1993 - "Phase II study of elliptinium acetate salvage treatment of advanced breast cancer."
01/01/1990 - "Elliptinium acetate in metastatic breast cancer--a phase II study."
07/01/1989 - "This study demonstrates that elliptinium has minimal activity in recurrent breast cancer with a favorable toxicity profile."
07/01/1989 - "Elliptinium: phase II study in advanced measurable breast cancer."
10/01/1988 - "Pharmacokinetic study of 14C-radiolabelled elliptinium acetate in patients with metastatic breast cancer."
|4.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/1988 - "Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma."
07/01/1985 - "Phase II trial of elliptinium in advanced renal cell carcinoma."
01/01/1988 - "Sixteen patients with adult metastatic renal cell carcinoma were treated with elliptinium acetate, 80 mg/m2.day, for 3 consecutive days every 3 weeks. "
07/01/1985 - "Elliptinium has modest activity in advanced renal cell cancer and does not produce myelosuppression."
07/01/1985 - "Forty patients with advanced renal cell carcinoma were treated with elliptinium by a weekly infusion of 100 mg/m2. "
|5.||Hepatocellular Carcinoma (Hepatoma)
01/01/1988 - "Fifteen patients with hepatocellular carcinoma were administered elliptinium acetate in a phase II trial. "
01/01/1988 - "In conclusion, elliptinium acetate has no valuable therapeutic impact on the treatment of hepatocellular carcinoma."
02/15/1988 - "Elliptinium acetate (EA) is a new anti-cancer compound displaying cytostatic activity against various malignancies including hepatoma. "
02/01/1986 - "[Randomized trial of elliptinium acetate and tamoxifen in the treatment of inoperable hepatocellular carcinoma]."
02/15/1988 - "Conjugates of elliptinium acetate with mouse monoclonal anti-alpha-fetoprotein antibodies or Fab fragments: in vitro cytotoxic effects upon human hepatoma cell lines."
|3.||Vinblastine (Vinblastine Sulfate)
|6.||elliptinium (elliptinium acetate)
|7.||DNA (Deoxyribonucleic Acid)
|9.||Glutathione (Reduced Glutathione)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)